Endokrinologie. Urogenitales Menopause-Syndrom mehr beachten

Der Terminus „vulvovaginale Atrophie“ bei postmenopausalen Frauen berücksichtigt zu wenig die Vielfalt an heterogenen Beschwerden, die damit assoziiert sind. Daher wurde 2014 in Chicago von einem internationalen Expertenteam eine Konsensuskonferenz der Nordamerikanischen Menopause-Gesellschaft einberufen. Der neue Terminus lautet nun „Urogenitales Menopausen-Syndrom“. Diese Bezeichnung ist medizinisch umfassender. Größere gesellschaftliche Akzeptanz wird davon erwartet. Immerhin leidet etwa die Hälfte der Frauen ab der Menopause an diesem Syndrom, aber nur wenige bekommen adäquate Therapie – so die internationale Expertenkommission.

• Literatur

• 1 Griesser H, Skonietzki S, Fischer T et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2 mg and 0.03 mg estriol. Maturitas 2012; 71: 360-368
• 2 The North American Menopause Society. The role of local vaginal estrogen for treatment of vaginal atrophy in postmenopausal women: 2007 position statement of the North American Menopause Society. Menopause 2007; 14: 355-363
• 3 Nappi RE, Kokot-Kierepa M. Womenʼs voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010; 67: 233-238
• 4 Puck A, Korte W, Hübner KA. Die Wirkung des Oestriol auf Corpus uteri, Cervix uteri und Vagina der Frau. Dtsch Med Wschr 1957; 82: 1864-1866
• 5 Gitsch E, Golob E. Zur Frage der idealen Oestriolkonzentration in Salben bei genitaler Anwendung. Zbl Gynaekol 1962; 84: 454-458
• 6 Suckling J, Lethaby A, Kennedy R. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006; (4) CD001500
• 7 North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010; 17: 242-255
• 8 Bergink EW. Oestriol receptor interactions: their biological importance and therapeutic implications. Acta Endocrinol (Copenh) 1980; 233: 9-16
• 9 Vooijs GP, Geurts TB. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol Reprod Biol 1995; 62: 101-106
• 10 Buhling KJ, Eydeler U, Borregaard S et al. Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries of vaginal atrophy. Arzneimittelforschung 2012; 62: 378-383
• 11 Dondres G, Neven P, Moegele M et al. CLINICAL TRIAL Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor®) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014; 145: 371-379
• 12 OʼMeara ES, Rossing MA, Daling JR et al. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. J Natl Cancer Inst 2001; 93: 754-762
• 13 Dew JE, Wren BG, Eden JA. A cohort study of topical vaginal estrogen therapy in women previously treated for breast cancer. Climacteric 2003; 6: 45-52
• 14 Lyytinen H, Pukkala E, Ylikorkala O. Breast cancer risk in postmenopausal women using estrogen-only therapy. Obstet Gynecol 2006; 108: 1354-1360
• 15 Head KA. Estriol: safety and efficacy. Altern Med Rev 1998; 3: 101-113
• 16 van der Vies J. The pharmacology of oestriol. Maturitas 1998; 4: 291-299
• 17 Anderson JN, Peck jr. EJ, Clark JH. Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. Endocrinology 1975; 96: 160-167
• 18 Schover LR, Baum GP, Fuson LA et al. Sexual problems during the first two years of adjuvant treatment with aromatase inhibitors. J Sex Med 2014; 11: 3102-3111
• 19 Wenderlein JM. Ein Drittel weniger Brustkrebs-Diagnosen unter HRT. Frauenarzt 2011; 52: 122-123
• 20 Wenderlein JM. Hormonsubstitution nach Brustkrebs. ÄP Gynäkologie 2014; 6: 10-11